Zopa Retreatment and Vector Shedding in Adults With RRP
← catalyst calendarNCT06538480 · readout in 470 d
Sponsored by Precigen, Inc (industry) · PGEN — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
30estimated
Sites
3
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-11 | actual | When the study began enrolling |
| Primary completion | 2027-12-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-12-02 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Recurrent Respiratory Papillomatosis
- Papillomavirus Infection
- Papillomaviridae
Intervention
- Drug: Zopapogene imadenovec (Zopa)
Primary outcomes
what the primary-completion date above is the date OFCohort 1 Vector shedding
measured Up to 6 weeks following last administration, with additional collections if needed until two consecutive measurements at or below limit of detection
Cohort 2 Complete Response Rate
measured 12 months following last administration
Permalink · PGEN's whole pipeline · Catalyst calendar · Every registered study · What changed